Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.

[1]  J. Feld,et al.  Hepatitis C virus infection , 2015, Canadian Medical Association Journal.

[2]  F. Brancati,et al.  Elevated ALT and GGT predict all-cause mortality and hepatocellular carcinoma in Taiwanese male: a case-cohort study , 2013, Hepatology International.

[3]  G. Heinze,et al.  Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer , 2013, British Journal of Cancer.

[4]  O. Weiland,et al.  A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Ding‐Shinn Chen,et al.  Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow‐up , 2013, Hepatology.

[6]  J. Everhart,et al.  Association of γ‐glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV) , 2013, Hepatology.

[7]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[8]  S. Juo,et al.  Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  S. Juo,et al.  Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin , 2012, PloS one.

[10]  H. El‐Serag,et al.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  Sheng-Nan Lu,et al.  A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. , 2012, The Journal of antimicrobial chemotherapy.

[12]  M. L. Maestro,et al.  Relation of IL28B Gene Polymorphism with Biochemical and Histological Features in Hepatitis C Virus-Induced Liver Disease , 2012, PloS one.

[13]  S. Juo,et al.  Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. , 2012, Antiviral research.

[14]  Y. Hiasa,et al.  Recent trends of Japanese hepatocellular carcinoma due to HCV in aging society. , 2011, Hepato-gastroenterology.

[15]  Ming‐Lung Yu,et al.  Chronic hepatitis C infection in the elderly , 2011, The Kaohsiung journal of medical sciences.

[16]  T. Berg,et al.  The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection , 2011, Journal of Gastroenterology.

[17]  L. Holmberg,et al.  Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons - the Swedish AMORIS study. , 2011, European journal of cancer.

[18]  M. Pirisi,et al.  IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. , 2011, Journal of hepatology.

[19]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[20]  Ming‐Lung Yu,et al.  Role of interleukin‐28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients , 2011, Hepatology.

[21]  Jeong Min Lee,et al.  Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma , 2010, Hepatology international.

[22]  Ming‐Lung Yu,et al.  Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. , 2010, The Journal of infectious diseases.

[23]  J. Everhart,et al.  Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. , 2009, Gastroenterology.

[24]  E. Vartiainen,et al.  Joint effects of coffee consumption and serum gamma‐glutamyltransferase on the risk of liver cancer , 2008, Hepatology.

[25]  Ming‐Lung Yu,et al.  Long-Term Effects of Interferon-Based Therapy for Chronic Hepatitis C , 2007, Oncology.

[26]  R. D. de Knegt,et al.  γ‐Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon‐α‐2b in chronic hepatitis C non‐responders , 2007 .

[27]  I. Sheen,et al.  Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386‐patient study from Taiwan , 2007, Alimentary pharmacology & therapeutics.

[28]  Sheng-Nan Lu,et al.  A Sustained Virological Response to Interferon or Interferon/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan , 2006, Antiviral therapy.

[29]  Y. Liaw,et al.  A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. , 2006, Hepatology.

[30]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[31]  C. Villela-Nogueira,et al.  Gamma-Glutamyl Transferase (GGT) as an Independent Predictive Factor of Sustained Virologic Response in Patients With Hepatitis C Treated With Interferon-Alpha and Ribavirin , 2005, Journal of clinical gastroenterology.

[32]  A. Paolicchi,et al.  Gamma‐glutamyltransferase in fine‐needle liver biopsies of subjects with chronic hepatitis C , 2005, Journal of viral hepatitis.

[33]  K. McGlynn,et al.  Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. , 2004, Gastroenterology.

[34]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[35]  K. Chayama,et al.  Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. , 1998, Journal of hepatology.

[36]  M. Sakamoto,et al.  Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. , 1993, The Journal of general virology.

[37]  P. Scheuer,et al.  Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.

[38]  V. Mazzaferro,et al.  EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .

[39]  S. Juo,et al.  Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. , 2012, Journal of hepatology.

[40]  Su Shu-hui.  Brief introduction to 2012 EASL-EORTC Clinical Practice Guidelines on the management of hepatocellular carcinoma , 2012 .

[41]  C. Villela-Nogueira,et al.  Predictors of response to chronic hepatitis C treatment. , 2010, Annals of hepatology.

[42]  William M. Lee,et al.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. , 2009, Gastroenterology.

[43]  R. D. de Knegt,et al.  Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. , 2007, Liver international : official journal of the International Association for the Study of the Liver.